ACW Stock Overview
Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological diseases in Australia.
Actinogen Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.071|
|52 Week High||AU$0.20|
|52 Week Low||AU$0.055|
|1 Month Change||-27.55%|
|3 Month Change||-20.23%|
|1 Year Change||-19.32%|
|3 Year Change||446.15%|
|5 Year Change||1.43%|
|Change since IPO||-91.34%|
Recent News & Updates
Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Actinogen Medical...
|ACW||AU Biotechs||AU Market|
Return vs Industry: ACW underperformed the Australian Biotechs industry which returned -9% over the past year.
Return vs Market: ACW underperformed the Australian Market which returned 0.5% over the past year.
|ACW Average Weekly Movement||13.9%|
|Biotechs Industry Average Movement||9.9%|
|Market Average Movement||9.3%|
|10% most volatile stocks in AU Market||16.3%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: ACW is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: ACW's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer’s disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer’s disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects.
Actinogen Medical Fundamentals Summary
|ACW fundamental statistics|
Is ACW overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACW income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0041|
|Net Profit Margin||-380.15%|
How did ACW perform over the long term?See historical performance and comparison
How is Actinogen Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Actinogen Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Actinogen Medical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACW is currently unprofitable.
Growing Profit Margin: ACW is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACW is unprofitable, and losses have increased over the past 5 years at a rate of 1.8% per year.
Accelerating Growth: Unable to compare ACW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).
Return on Equity
High ROE: ACW has a negative Return on Equity (-29.92%), as it is currently unprofitable.
How is Actinogen Medical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ACW's short term assets (A$22.6M) exceed its short term liabilities (A$955.5K).
Long Term Liabilities: ACW's short term assets (A$22.6M) exceed its long term liabilities (A$126.8K).
Debt to Equity History and Analysis
Debt Level: ACW is debt free.
Reducing Debt: ACW has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACW has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ACW has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 1.3% each year.
What is Actinogen Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACW's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACW's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ACW has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Gourlay (61 yo)
Dr. Steven G. Gourlay, also known as Steve, MBBS (M.D.), Ph D., FRACP, M.B.A., serves as Chief Executive Officer at Actinogen Medical Limited since March 15, 2021 and as its Managing Director and Director...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD192.68K) is below average for companies of similar size in the Australian market ($USD287.06K).
Compensation vs Earnings: Insufficient data to compare Steve's compensation with company performance.
Experienced Management: ACW's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: ACW's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ACW insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.2%.
Actinogen Medical Limited's employee growth, exchange listings and data sources
- Name: Actinogen Medical Limited
- Ticker: ACW
- Exchange: ASX
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$126.355m
- Shares outstanding: 1.78b
- Website: https://www.actinogen.com.au
- Actinogen Medical Limited
- 109 Pitt Street
- Suite 901
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.